中国医药科学2024,Vol.14Issue(2) :20-24.DOI:10.20116/j.issn2095-0616.2024.02.05

结缔组织病相关间质性肺病的生物标志物研究进展

Research progress on biomarkers of connective tissue disease-associated interstitial lung disease

陈萍 武剑
中国医药科学2024,Vol.14Issue(2) :20-24.DOI:10.20116/j.issn2095-0616.2024.02.05

结缔组织病相关间质性肺病的生物标志物研究进展

Research progress on biomarkers of connective tissue disease-associated interstitial lung disease

陈萍 1武剑1
扫码查看

作者信息

  • 1. 苏州大学附属第一医院风湿免疫科,江苏苏州 215000
  • 折叠

摘要

结缔组织病是由于免疫功能紊乱所导致的一类自身免疫性疾病,常有多系统受累.肺部受累是结缔组织病最常见的并发症之一,其中以间质性肺病最为多见.目前免疫机制等相关研究证实了结缔组织病相关间质性肺病(CTD-ILD)发病机制的复杂性,同时也为临床提供新的诊疗思路.本文将总结并讨论CTD-ILD主要候选生物标志物GM-CSF、IL、S100A8/A9、CA153、MUC5B等,通过回顾机制、潜力、局限性及在不同CTD-ILD中的临床应用,帮助指导未来临床研究及实践,降低临床漏诊率,实现早期治疗,从而改善患者预后.

Abstract

Connective tissue disease is a type of autoimmune disease caused by immune dysfunction,often involving multiple systems.Lung involvement is one of the most common complications of connective tissue disease,with interstitial lung disease being the most common.At present,relevant studies on immune mechanisms have confirmed the complexity of the pathogenesis of connective tissue disease-associated interstitial lung disease(CTD-ILD),and also provide new clinical diagnostic and treatment ideas.This article will summarize and discuss the main candidate biomarkers of interstitial lung disease related to connective tissue disease,such as GM-CSF,IL,S100A8/A9,CA153,MUC5B,etc.by reviewing the mechanisms,potential,limitations,and clinical applications in different CTD-ILD,which will help guide future clinical research and practice,reduce clinical missed diagnosis rates,conduct early treatment,and improve patient prognosis.

关键词

结缔组织病/间质性肺病/结缔组织病相关间质性肺病/生物标志物

Key words

Connective tissue disease/Interstitial lung disease/Connective tissue disease-associated interstitial lung disease/Biomarkers

引用本文复制引用

基金项目

江苏省苏州市科技发展计划(SLJ2021009)

出版年

2024
中国医药科学
海峡两岸医药卫生交流协会 二十一世纪联合创新(北京)医药科学研究院

中国医药科学

影响因子:1.083
ISSN:2095-0616
参考文献量10
段落导航相关论文